文献速递肝病消化道肿瘤与早癌

IMbrave150研究更新疗效与安全性数据:阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2021-12-11

IMbrave150是一项开放标签III期研究,501例不可切除肝细胞癌患者按2:1随机接受阿替利珠单抗联合贝伐珠单抗(n=336)或索拉非尼(n=165)。中位随访15.6个月后,联合组中位总生存19.2个月(95%CI 17.0-23.7) vs 索拉非尼组13.4个月(95%CI 11.4-16.9),HR 0.66(95%CI 0.52-0.85;描述性p<0.001)。

要点

  • 中位随访15.6个月,联合组中位OS 19.2个月 vs 索拉非尼组13.4个月(HR 0.66;95%CI 0.52-0.85)。
  • 联合组中位PFS 6.9个月 vs 索拉非尼组4.3个月(HR 0.65;95%CI 0.53-0.81)。
  • 治疗相关3/4级不良事件联合组143/329(43%) vs 索拉非尼组72/156(46%)。

核心结论

  • 更长时间随访后,阿替利珠单抗联合贝伐珠单抗较索拉非尼维持有临床意义的生存获益,安全性特征与主要分析一致。
  • 更新结果确认阿替利珠单抗联合贝伐珠单抗为晚期肝细胞癌一线标准治疗。

研究设计与样本

  • 开放标签III期研究,纳入系统治疗初治的不可切除肝细胞癌患者,按2:1随机分配。
  • 联合组接受阿替利珠单抗1200 mg联合贝伐珠单抗15 mg/kg静脉给药每3周一次;索拉非尼组口服400 mg每日两次。
  • 2018年3月15日至2019年1月30日随机分配501例患者(意向治疗人群):联合组336例,索拉非尼组165例。
  • 共同主要终点为意向治疗人群独立评估RECIST 1.1的总生存和无进展生存;本次为事后更新疗效与安全性分析。

主要发现

  • 截至2020年8月31日,中位随访15.6个月(范围0-28.6个月),联合组中位OS 19.2个月(95%CI 17.0-23.7) vs 索拉非尼组13.4个月(95%CI 11.4-16.9),HR 0.66(95%CI 0.52-0.85;描述性p<0.001)。
  • 联合组中位PFS 6.9个月(95%CI 5.7-8.6) vs 索拉非尼组4.3个月(95%CI 4.0-5.6),HR 0.65(95%CI 0.53-0.81;描述性p<0.001)。
  • 治疗相关3/4级不良事件在联合组安全可评估患者中发生143/329(43%),索拉非尼组72/156(46%)。
  • 治疗相关5级事件在联合组发生6/329(2%),索拉非尼组1/156(<1%)。

关键数值与推荐

  • 联合组中位OS 19.2个月(95%CI 17.0-23.7) vs 索拉非尼组13.4个月(95%CI 11.4-16.9),HR 0.66(95%CI 0.52-0.85;描述性p<0.001)。
  • 联合组中位PFS 6.9个月(95%CI 5.7-8.6) vs 索拉非尼组4.3个月(95%CI 4.0-5.6),HR 0.65(95%CI 0.53-0.81;描述性p<0.001)。

临床怎么用

  • 更新结果确认阿替利珠单抗联合贝伐珠单抗为晚期肝细胞癌一线标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared with sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of follow-up). We present updated data after 12 months of additional follow-up. METHODS: Patients with systemic treatment-naive, unresectable hepatocellular carcinoma were randomized 2:1 to receive 1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily in this open-label, phase III study. Co-primary endpoints were OS and PFS by independently assessed RECIST 1.1 in the intention-to-treat population. Secondary efficacy endpoints included objective response rates and exploratory subgroup efficacy analyses. This is a post hoc updated analysis of efficacy and safety. RESULTS: From March 15, 2018, to January 30, 2019, 501 patients (intention-to-treat population) were randomly allocated to receive atezolizumab plus bevacizumab (n = 336) or sorafenib (n = 165). On August 31, 2020, after a median 15.6 (range, 0-28.6) months of follow-up, the median OS was 19.2 months (95% CI 17.0-23.7) with atezolizumab plus bevacizumab and 13.4 months (95% CI 11.4-16.9) with sorafenib (hazard ratio [HR] 0.66; 95% CI 0.52-0.85; descriptive p <0.001). The median PFS was 6.9 (95% CI 5.7-8.6) and 4.3 (95% CI 4.0-5.6) months in the respective treatment groups (HR 0.65; 95% CI 0.53-0.81; descriptive p < 0.001). Treatment-related grade 3/4 adverse events occurred in 143 (43%) of 329 and 72 (46%) of 156 safety-evaluable patients in the respective groups, and treatment-related grade 5 events occurred in 6 (2%) and 1 (<1%) patients. CONCLUSION: After longer follow-up, atezolizumab plus bevacizumab maintained clinically meaningful survival benefits over sorafenib and had a safety profile consistent with the primary analysis. GOV IDENTIFIER: NCT03434379. LAY SUMMARY: The primary analysis of IMbrave150 showed that atezolizumab plus bevacizumab had significantly greater benefits than sorafenib in patients with advanced hepatocellular carcinoma, but survival data were not yet mature. At this updated analysis done 12 months later, median overall survival was 5.8 months longer with atezolizumab plus bevacizumab than sorafenib, and the severity profile of treatment-related side effects remained similar. These updated results confirm atezolizumab plus bevacizumab as the first-line standard of care for advanced hepatocellular carcinoma.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021. PMID: 34902530. doi:10.1016/j.jhep.2021.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。